Neuroscience Daily for 12 September follows 3 stories from r/neuro and r/neuroscience, moving through conscious intention, structured learning, brain organoids.Chapters 00:00:00 — Intro 00:00:06 — Conscious Intention 00:01:07 — Structured Learning 00:02:09 — Brain Organoids 00:03:12 — Closing 1. Conscious Intention The first story is about conscious intention, from a paper in Cerebral Cortex. The researchers asked 51 people to type words in a verbal-fluency task and interrupted them at

Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical Executive’s weekly biotech roundup gathers analyst reaction to the week's biggest stories, and Nate Hill of Strive Pharmacy talks through the regulatory uncertainty around compounded peptides.

In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.

Ultragenyx shares plunge after apazunersen fails its Phase III trial in Angelman syndrome, Mark Cziraky of Carelon Research talks through the mechanics of analyzing linked real-world data sets, and Melanie Whittington joins The Ron Lanton Report to argue biopharma policy needs to stay tethered to patients, not abstractions.

🔥😱 في هذا الفيديو، يرد موزو على تهديد إيناس في موقف مفاجئ ومليء بالتوتر! 💥😤 تتصاعد الأحداث وتظهر ردود فعل غير متوقعة، مما يثير فضول المتابعين لمعرفة ما الذي حدث بينهما. 👀🔥❤️ شاهدوا الفيديو حتى النهاية لمعرفة تفاصيل الموقف، ولا تنسوا الإعجاب 👍 والتعليق 💬 والاشتراك في القناة 🔔.

In today's ACT Brief, we examine why black-box AI fails in clinical trials, how participant understanding drives engagement more than gamification, and FDA permanent leadership appointments prioritizing regulatory predictability.

Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and Tom Rotolo make the case for real-world insights in obesity medical strategy.

In today's ACT Brief, we examine how regulatory guidance and financial evidence enable RBQM adoption, why site payment performance remains a competitive differentiator, and a collaboration advancing an inhaled approach to cystic fibrosis.

In this episode of STBYM’s The Monstrefact, Robert discusses the alien creature known as the Hollow on the series “Scavenger’s Reign.”See omnystudio.com/listener for privacy information.

The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaiming licenses its tri-specific antibody Sim0660 to Roche for up to $1.53 billion.

In today's ACT Brief, we examine value hidden in the RBQM financial model, why rare disease research leads on genuine patient partnership, and how safety concerns shape IBD treatment decisions despite clinical efficacy.

💔😱 في هذا الفيديو، تعيش إيناس موقفًا مفاجئًا أثناء الطريق، وسط أجواء من التوتر والقلق، بينما يحاول موزو التعامل مع الموقف ومساندتها. 🚗🔥👀 لحظات غير متوقعة وردود فعل عفوية تجعل الأحداث أكثر إثارة، وتترك المتابعين في فضول لمعرفة ما الذي حدث وكيف انتهى الموقف. 😱✨🎥 تابعوا الفيديو حتى النهاية لاكتشاف التفاصيل كاملة!👍 لا تنسوا الإعجاب، التعليق، والاشتراك في القناة لمتابعة المزيد من المقاطع المميزة. ❤️🔥

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and Parth Khanna argues that more competitive data doesn't mean better intelligence in pharma.